Cartesian Therapeutics Inc. (RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, has a clinical trial catalyst to watch in the coming months.
The company's lead drug candidate is DESCARTES-08, currently under a phase IIb trial in patients with generalized myasthenia gravis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com